Advisory Group: ‘Near Perfect Storm’ Coming On Gene Patents In The US
A report by a United States health department advisory group issued last week presents recommendations aimed at preventing patents on genes and licensing practices in the US from negatively impacting patient access to genetic tests that would allow them to establish their genetic dispositions to declare potential illnesses.

Daniele Dionisio argues some perspectives on health and IP might change now that controversial practices at the WTO, World Bank and IMF are increasingly under pressure, and that new government policy choices and actors on the world chessboard are emerging.